Cargando…

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial

BACKGROUND: The presence of tumour-infiltrating lymphocytes (TILs) is associated with response to neoadjuvant chemotherapy among patients with triple-negative and HER2-positive breast cancer. However, the significance of TILs is less clear in luminal breast cancer. Here, we in postmenopausal patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skriver, Signe Korsgaard, Jensen, Maj-Britt, Knoop, Ann Soegaard, Ejlertsen, Bent, Laenkholm, Anne-Vibeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222485/ https://www.ncbi.nlm.nih.gov/pubmed/32410705 http://dx.doi.org/10.1186/s13058-020-01285-8

Ejemplares similares

Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial
por: Shenasa, Elahe, et al.
Publicado: (2022)

First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG
por: Celik, Alan, et al.
Publicado: (2022)

High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
por: Nielsen, Kåre, et al.
Publicado: (2023)

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020)

Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG Study
por: Lyng, Maria B., et al.
Publicado: (2013)

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study
por: Buhl, Anna Sofie Kappel, et al.
Publicado: (2018)

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study
por: Lyng, Maria B., et al.
Publicado: (2012)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
por: Jensen, Maj-Britt, et al.
Publicado: (2018)

Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)
por: Berg, Tobias, et al.
Publicado: (2020)

Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
por: Olafsdottir, Elinborg J., et al.
Publicado: (2020)

Statin use and risk of contralateral breast cancer: a nationwide cohort study
por: Langballe, Rikke, et al.
Publicado: (2018)

Danish Breast Cancer Cooperative Group
por: Christiansen, Peer, et al.
Publicado: (2016)

Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
por: Miller, William R, et al.
Publicado: (2010)

Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG)
por: Cold, S, et al.
Publicado: (2005)

The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study
por: Bens, Annet, et al.
Publicado: (2020)

Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study
por: Cold, Søren, et al.
Publicado: (2022)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Letrozole in the neoadjuvant setting: the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Letrozole in the neoadjuvant setting the P024 trial
por: Ellis, Matthew J., et al.
Publicado: (2007)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
por: Colon-Otero, Gerardo, et al.
Publicado: (2020)

Selection criteria for early breast cancer patients in the DBCG proton trial – The randomised phase III trial strategy
por: Stick, Line Bjerregaard, et al.
Publicado: (2021)

Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review
por: Marina, Djordje, et al.
Publicado: (2022)

Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial
por: Thomsen, M.S., et al.
Publicado: (2021)

Foetal oestrogens and autism
por: Baron-Cohen, Simon, et al.
Publicado: (2019)

Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status
por: Rossing, Maria, et al.
Publicado: (2021)

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
por: Fasching, Peter A, et al.
Publicado: (2014)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
por: Kim, Jisun, et al.
Publicado: (2014)

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours
por: Selli, Cigdem, et al.
Publicado: (2019)

The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
por: Stovgaard, Elisabeth S, et al.
Publicado: (2021)

Incidence Rates of Deliberate Self-Harm in Denmark 1994–2011: A Nationwide Register Study
por: Reuter Morthorst, Britt, et al.
Publicado: (2016)

Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling
por: Larsen, Martin J., et al.
Publicado: (2013)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials
por: Kyndi, Marianne, et al.
Publicado: (2008)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
por: Kodahl, Annette R., et al.
Publicado: (2018)

Rates of re‐excision and conversion to mastectomy after breast‐conserving surgery with or without oncoplastic surgery: a nationwide population‐based study
por: Heeg, E., et al.
Publicado: (2020)

Immunophenotype of the lymphoid cell infiltrates in breast carcinomas of low oestrogen receptor content.
por: Underwood, J. C., et al.
Publicado: (1987)

Of Oestrogens and Sperm: A Review of the Roles of Oestrogens and Oestrogen Receptors in Male Reproduction
por: Dostalova, Pavla, et al.
Publicado: (2017)

Intratumor Genetic Heterogeneity of Breast Carcinomas as Determined by Fine Needle Aspiration and TaqMan Low Density Array
por: Lyng, Maria B., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_0cdec59iafupplosiocl820nqg